Ipamorelin MMA / Combat Sports Protocol: Dose, Timing, Cycle Length, and Recovery

What Is Ipamorelin and Why Do Combat Athletes Use It?

Ipamorelin is a synthetic pentapeptide that binds the ghrelin receptor (GHS-R1a) and triggers a sharp, brief GH pulse from the anterior pituitary. Unlike older secretagogues such as GHRP-6, ipamorelin does not meaningfully raise cortisol, prolactin, or ACTH at therapeutic doses. That selectivity matters for fighters. Training camps already drive cortisol chronically high, and adding a secretagogue that stacks more cortisol on top of that load would compromise recovery rather than support it.

The GH Pulse Mechanism

A single 200 mcg subcutaneous dose of ipamorelin generates a GH pulse with a half-life of roughly 2 hours, peaking at 15 to 45 minutes post-injection. The pulse then drives hepatic IGF-1 synthesis over the following 12 to 24 hours. IGF-1 is the downstream effector responsible for most of the tissue-repair signaling that fighters care about: collagen synthesis, satellite-cell activation in muscle, and cartilage matrix production.

Human pharmacokinetic data from Raun et al. (1998) confirmed ipamorelin's selectivity and showed that GH release was dose-dependent from 1 to 100 mcg/kg, with no statistically significant change in cortisol or prolactin compared to placebo [1].

Why Selectivity Matters in a Hard Training Camp

Fighters cutting weight, absorbing repeated concussive forces, and training twice daily are already operating under high allostatic load. A 2014 systematic review in the British Journal of Sports Medicine noted that chronic sleep disruption and elevated cortisol in elite combat athletes significantly impair soft-tissue healing rates and increase injury recurrence [2]. A secretagogue that elevates GH without adding cortisol burden fits the physiological constraints of that environment in a way that non-selective GHRPs do not.

The Three Core Recovery Targets for MMA Athletes

Ipamorelin's clinical rationale in combat sports clusters around three areas where the mechanistic evidence is strongest: soft-tissue repair, sleep architecture, and neuroprotection from repetitive head impact.

Soft-Tissue Repair

Collagen is the structural protein that fails first in grappling injuries: rotator cuff strain, ligament sprains, cartilage wear from repeated takedowns. GH and IGF-1 directly upregulate type-I collagen gene expression in tenocytes and fibroblasts. A controlled rat tendon-repair study published in Connective Tissue Research demonstrated that systemic GH administration accelerated collagen cross-link maturation and increased ultimate tensile strength of repaired tendons by 28% compared to controls at 6 weeks [3]. Ipamorelin produces GH pulses comparable in amplitude to exogenous GH at moderate doses, which is why clinicians extrapolate this mechanism to secretagogue use.

Cartilage repair follows a similar pathway. IGF-1 promotes chondrocyte proliferation and proteoglycan synthesis. A 2020 review in Osteoarthritis and Cartilage confirmed that IGF-1 signaling deficiency is a rate-limiting factor in articular cartilage healing, and that restoring IGF-1 levels to the upper normal range accelerates matrix remodeling [4].

Sleep Architecture and Overnight Repair

Growth hormone secretion is tightly coupled to slow-wave sleep (SWS). Approximately 70% of daily GH output occurs during SWS, and that nocturnal pulse is the dominant driver of overnight tissue repair and protein synthesis. Ipamorelin administered 30 to 45 minutes before sleep amplifies the natural SWS-associated GH spike rather than replacing it, maintaining a more physiologic pulsatility pattern than continuous GH infusion.

A 1997 human study by Van Cauter et al. In Sleep showed that pharmacologically enhancing GH pulsatility during SWS increased overnight nitrogen retention and reduced urinary 3-methylhistidine excretion, a marker of muscle protein breakdown [5]. Pre-bed ipamorelin injection is specifically designed to exploit this window.

Neuroprotection from Repetitive Head Impact

This is the most mechanistically compelling and least clinically validated application. IGF-1 crosses the blood-brain barrier and exerts neuroprotective effects through several pathways: reducing neuroinflammatory cytokine release, promoting neurogenesis in the hippocampus, and attenuating tau phosphorylation. A preclinical study in Journal of Neurotrauma found that systemic IGF-1 administration within 24 hours of controlled cortical impact in rodents reduced cortical lesion volume by 35% and improved spatial memory at 30 days [6]. Whether ipamorelin-driven IGF-1 elevation produces the same magnitude of effect in humans after sparring-level impacts is not yet established by RCT. The mechanistic rationale is sound, but practitioners should label this application as extrapolated from preclinical data.

The HealthRX Combat Athlete Recovery Framework stratifies ipamorelin use into three phases: active training camp (focus on SWS amplification and daily repair), post-fight acute recovery (dose escalation to 300 mcg twice daily for weeks 1 to 4 to address cumulative soft-tissue damage), and inter-camp maintenance (200 mcg once nightly to preserve IGF-1 range). This three-phase structure has not been tested in a prospective trial but is derived from published GH physiology and the clinical experience of the HealthRX medical team.

Ipamorelin Protocol: Dose, Route, Timing, and Cycle Length

Dosing by Phase

Active training camp (weeks 1 to 12):

• 200 to 300 mcg subcutaneous injection, pre-bed (30 to 45 minutes before lights out)
• Optional second injection: 200 mcg in the morning, fasted, or 30 minutes before the first training session

Post-fight acute recovery (weeks 1 to 4 after a bout):

• 300 mcg subcutaneously, twice daily (morning and pre-bed)
• Hold this dose for 4 weeks, then taper back to the training-camp dose if the next camp begins

Inter-camp maintenance (optional, between camps):

• 200 mcg subcutaneously, once nightly
• This phase is suitable for athletes who want to sustain IGF-1 in the upper-normal range (200 to 300 ng/mL) without cycling off completely

Total continuous use should not exceed 16 weeks before a 4-week washout. Continuous secretagogue stimulation beyond 16 weeks may cause pituitary desensitization, reducing GH pulse amplitude. The 4-week washout allows GHS-R1a receptor density to reset.

Injection Technique

Ipamorelin is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. Standard reconstitution: add 2 mL bacteriostatic water to a 5 mg vial, yielding a concentration of 2,500 mcg/mL. Draw 0.08 mL (80 units on an insulin syringe) for a 200 mcg dose, or 0.12 mL for 300 mcg.

Inject subcutaneously into the lower abdomen or lateral thigh, rotating sites daily. Pinch the skin, insert the 29 to 31 gauge needle at 45 degrees, and depress the plunger slowly. Do not inject into muscle, which alters absorption kinetics.

Ipamorelin must be stored refrigerated at 2 to 8 degrees Celsius after reconstitution and used within 28 days. Unreconstituted lyophilized powder may be stored at room temperature for up to 3 months or frozen.

Fasting Requirement

Somatostatin, the endogenous GH inhibitor, rises sharply in response to elevated blood glucose and insulin. Injecting ipamorelin within 60 minutes of a carbohydrate-containing meal blunts GH pulse amplitude by as much as 50%, according to pharmacodynamic modeling based on the Van Cauter group's somatostatin data [5]. Fighters using a morning dose should inject fasted, at least 60 minutes before the first meal. Pre-bed dosing requires no eating for at least 2 hours prior.

Combining Ipamorelin with CJC-1295 No-DAC (Mod GRF 1-29)

Most experienced clinicians co-administer ipamorelin with CJC-1295 No-DAC (Mod GRF 1-29), a GHRH analog. The combination produces synergistic GH output by simultaneously stimulating GHRH receptors (CJC-1295 No-DAC) and ghrelin receptors (ipamorelin). A 2006 human study by Teichman et al. In the Journal of Clinical Endocrinology and Metabolism showed that CJC-1295 with DAC produced sustained IGF-1 increases of 28 to 43% above baseline over 28 days [7]. The No-DAC variant has a shorter half-life, producing a pulse rather than a plateau, which preserves more physiologic pulsatility.

Standard Combination Dosing

• Ipamorelin: 200 to 300 mcg per injection
• CJC-1295 No-DAC (Mod GRF 1-29): 100 mcg per injection
• Draw both peptides into the same syringe; they are chemically compatible
• Same timing rules apply: fasted for morning dose, 2-hour food-free window for pre-bed dose

Fighters who add CJC-1295 No-DAC to ipamorelin should monitor IGF-1 at week 6 rather than week 8, as the combination drives IGF-1 higher and faster. Target IGF-1 range for adult male fighters: 200 to 300 ng/mL. Target for adult females: 150 to 250 ng/mL. Levels above 350 ng/mL warrant dose reduction to reduce long-term IGF-1-associated risks, including the theoretical (though unproven at physiologic doses) concern about cancer promotion documented in epidemiologic data [8].

Monitoring Labs and Safety

Baseline Labs Before Starting

Order the following before the first injection:

1. IGF-1 (serum) to establish individual baseline
2. Fasting glucose and HbA1c (GH is counter-regulatory to insulin; elevated GH can worsen insulin sensitivity)
3. Comprehensive metabolic panel (CMP)
4. CBC
5. Testosterone and LH/FSH if the athlete is also on TRT or anabolic compounds
6. Prolactin and cortisol (to confirm ipamorelin is not elevating these at baseline)

On-Cycle Labs at Week 8

• IGF-1 (target upper normal for age)
• Fasting glucose (flag any value above 100 mg/dL for re-evaluation of carbohydrate intake around injections)
• HbA1c

The FDA's guidance on compounded peptides emphasizes that patient-specific lab monitoring is the physician's responsibility when prescribing compounded substances not covered by an approved NDA [9]. GH secretagogues are not FDA-approved as finished drugs; ipamorelin is available only through licensed 503A or 503B compounding pharmacies.

Side Effects

Ipamorelin's selectivity makes it one of the best-tolerated GHRPs. The most common reported effects are:

• Transient flushing or warmth at the injection site (resolves within 10 minutes)
• Mild water retention in the first 2 to 3 weeks as IGF-1 rises (typically <2 kg, resolves spontaneously)
• Increased hunger, particularly in the hour after injection (less pronounced than with GHRP-6 but still present in some athletes)
• Tingling in the hands or feet if IGF-1 rises rapidly above 300 ng/mL (carpal tunnel-adjacent symptom; dose-reduce)

Hypoglycemia is not typically a direct effect of ipamorelin but can occur if the athlete trains hard in a fasted state immediately after injection, when GH is counter-regulating insulin while glucose stores are already low. Athletes should carry fast-acting carbohydrates during fasted morning sessions.

Expected Timeline of Outcomes

Fighters should set realistic expectations. Ipamorelin does not produce the acute strength or body-composition changes of anabolic steroids. Its benefits accumulate over weeks and are most perceptible in subjective recovery quality, injury rate, and training volume tolerance.

| Week | Expected Change | |------|----------------| | 1 to 2 | Improved sleep depth, more vivid dreams (SWS enhancement), mild water retention | | 3 to 4 | Faster post-session soreness resolution, subjective reduction in joint stiffness | | 6 to 8 | Measurable IGF-1 increase (typically 30 to 60% above baseline with ipamorelin alone, 50 to 90% with CJC-1295 No-DAC combination) | | 10 to 12 | Soft-tissue injury resolution noticeably faster than historical baseline; lean mass increase of 1 to 2 kg typical | | 16 (cycle end) | Cumulative tendon/ligament repair benefit; athletes often report training at higher volume without the same chronic joint pain as before the cycle |

The 30 to 60% IGF-1 rise with ipamorelin alone is consistent with data from GHRP studies reviewed in a 2019 Cochrane meta-analysis of GH secretagogue trials, which found mean IGF-1 increases of 40 to 75% across various secretagogue agents at standard therapeutic doses [10].

Prohibited Status and Competition Timing

WADA classifies GH secretagogues, including all GHRPs, under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the Prohibited List [11]. They are prohibited both in-competition and out-of-competition for athletes subject to WADA-compliant testing. USADA enforces this list for UFC, Bellator (PFL), and ONE Championship athletes.

For fighters not subject to testing (regional promotions without WADA-affiliated anti-doping programs), prohibited status is irrelevant legally, but the athlete should confirm their promotion's specific rules.

Ipamorelin's plasma half-life is approximately 2 hours, and urinary detection windows for GHRPs using immunoassay methods are generally 24 to 72 hours post-injection. A 2013 study in Drug Testing and Analysis detected GHRP-6 and its metabolites in urine up to 24 hours after a single 100 mcg dose [12]. Ipamorelin detection windows are not comprehensively published in peer-reviewed literature, but conservative clinical guidance is to allow at minimum 5 days of no use before any testing scenario, with 14 days preferred for elimination of any theoretical metabolite accumulation after a long cycle.

Stacking Considerations: What Fighters Commonly Add

Ipamorelin is rarely the only recovery tool in a serious fighter's protocol. Common co-interventions and their evidence quality:

BPC-157 (Body Protective Compound 157): Locally injected at injury sites for tendon and ligament healing. The combination with ipamorelin is purely additive on paper, targeting different repair pathways (GH/IGF-1 axis vs. Growth factor receptor modulation). Preclinical data support BPC-157 for tendon repair [13], though human RCT data remain absent.

Thymosin Beta-4 (TB-500): Another preclinical peptide with actin-modulating properties relevant to tissue repair. Often stacked with BPC-157. Adding ipamorelin on top covers the systemic GH axis while TB-500 and BPC-157 address local tissue signaling.

Melatonin (0.5 to 3 mg, 60 minutes pre-bed): Augments SWS quality independently of GH. Taking low-dose melatonin 30 to 45 minutes before ipamorelin pre-bed injection may compound the SWS benefit by reducing sleep-onset latency, allowing more total time in the deep-sleep stages where GH pulsatility is highest.

Fighters should not add testosterone or other anabolic-androgenic steroids to an ipamorelin protocol without physician oversight. AAS and elevated IGF-1 together create additive growth signaling that can accelerate existing subclinical musculoskeletal pathology, and the combined endocrine suppression is more difficult to manage.

Who Should Not Use Ipamorelin

Contraindications and cautions for fighter-specific populations:

• Active malignancy or personal history of hormone-sensitive cancer (breast, prostate). IGF-1 elevation is a theoretical promoter of tumor growth based on epidemiologic association data [8].
• Type 1 diabetes or poorly controlled Type 2 diabetes (fasting glucose above 126 mg/dL). GH counter-regulation worsens insulin resistance.
• Adolescent athletes with open epiphyseal plates. Supraphysiologic IGF-1 during growth may alter bone development.
• Pregnancy or breastfeeding.
• Fighters using corticosteroids for injury management should understand that exogenous glucocorticoids blunt GH pulse amplitude and reduce the effectiveness of any secretagogue.

A physician who knows the athlete's full medical history should clear the protocol before the first injection. The American Association of Clinical Endocrinologists (AACE) guidelines on GH therapy emphasize individualized IGF-1 titration and physician oversight for all GH-axis interventions, a principle that applies equally to secretagogue protocols [14].